# Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital

**Authors:** Bright Awadh Sangiwa, Celeste Burger, Annare Ellmann

PMC · DOI: 10.11604/pamj.2024.48.30.38084 · The Pan African Medical Journal · 2024-05-30

## TL;DR

This study evaluates how effective 68Ga PSMA PET/CT scans are in detecting prostate cancer recurrence, finding higher detection rates with higher PSA levels.

## Contribution

The study provides local clinical data on 68Ga PSMA PET/CT effectiveness in prostate cancer recurrence detection.

## Key findings

- 68Ga PSMA PET/CT detected recurrence in 66% of scans.
- Detection rates increased with higher PSA levels (86% at PSA ≥2 ng/ml).
- Gleason score did not predict scan positivity.

## Abstract

prostate cancer recurrence after definitive therapy for organ-confined disease often manifests as rising prostate-specific antigen (PSA) levels without clinically overt disease. 68Gallium prostate-specific membrane antigen, positron emission tomography/computed tomography (68GaPSMA PET/CT) imaging plays a major role in the management of recurrent prostate cancer. The purpose of this study was to assess the positivity rate of 68Ga PSMA PET/CT scans in cases of prostate cancer recurrence, and to compare the results with existing international literature.

a retrospective analysis of 177 68Ga PSMA PET/CT scans of patients with biochemically proven disease recurrence was performed. The possible association of a positive PSMA PET/CT with the PSA level and Gleason score were analyzed.

a total of 177 68Ga PSMA PET/CT scans were performed in 163 patients (median age 66 years). Of these, 117 (66%) scans detected the site of disease recurrence. Among patients with PSA 0.2-0.99 ng/ml, 23/49 (47%, p<0.0001) were positive, and 20/35 (57%, p<0.0005) were positive in the group of patients with PSA 1.00-1.99. When PSA values were further categorized into PSA <2 ng/ml and PSA ≥2 ng/ml, detection rates were 49% and 86% respectively (p <0.0001). The scans were positive in 65% of patients with Gleason score of <7, 62% with Gleason score of =7 and 68% with Gleason score >7 (p=0.745).

there was an increase in the detection rate with an increase in the PSA. Gleason score was not a predictor of a positive 68Ga PSMA PET/CT scan. 68Ga-PSMA PET/CT should be prioritized in patients with biochemical recurrence with PSA levels >0.2 ng/ml.

## Linked entities

- **Chemicals:** Gallium-68 (PubChem CID 5488452)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** FOLH1 (folate hydrolase 1) [NCBI Gene 2346] {aka FGCP, FOLH, GCP2, GCPII, NAALAD1, PSM}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}
- **Diseases:** prostate cancer (MESH:D011471)
- **Chemicals:** 68GaPSMA (MESH:C000718244), 68Gallium prostate-specific membrane antigen (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11364939/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11364939/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC11364939/full.md

---
Source: https://tomesphere.com/paper/PMC11364939